BioMark Diagnostics AAQS

Mitä BioMark Diagnostics tekee? BioMark Diagnostics, Inc. generates revenue by developing and commercializing cancer diagnostic solutions designed to detect, monitor, and assess treatment for cancer. The company leverages a molecular diagnostics technology platform that combines metabolomics and machine learning algorithms to enable physicians to detect carcinomas in pre-symptomatic stages. This approach aims to improve cancer prognosis and allows for measuring response to treatment as well as serial monitoring of cancer survivors. The firm focuses on cancers that are difficult to detect and treat by utilizing its liquid biopsy assay to detect Spermidine/spermine N-acetyltransferase 1, an enzyme with elevated levels in numerous cancers. Additionally, the company has developed a high-powered liquid biopsy metabolic panel assay which is instrumental for the early-stage diagnosis of lung cancer. These products serve the medical market by providing advanced tools for early detection and ongoing patient management. BioMark Diagnostics on yksi Eurpooliin suosituimmista yhtiöistä.